Epigenetic therapy supplements docetaxel in the treatment of lung cancer: an in vitro evaluation
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: JAIN, Prateek (Decision Resources Group, Biopharma Insights, Gurgaon, India)
- Co-author(s): Nayanabhirama Udupa Manipal University, India
Docetaxel (DTX) is one of the most effective chemotherapeutic agents in the treatment of non-small cell lung cancer. Unfortunately, there is altered response to DTX due to resistance. DNA methylation, an epigenetic event, plays a vital role in cancer and chemotherapy drug resistance. Exploiting the gene reactivation by using.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.